639 patents
Page 5 of 32
Utility
Methods of Assessing Suitability of Use of Pharmaceutical Compositions of Albumin and Poorly Water Soluble Drug
3 Aug 23
The present invention provides methods of assessing suitability of a pharmaceutical composition for medical use.
Viktor PEYKOV, Willard FOSS, Daniel W. PIERCE, Neil P. DESAI
Filed: 27 Sep 22
Utility
Fibronectin Based Scaffold Proteins
3 Aug 23
Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided.
Dasa LIPOVSEK, Jonathan H. DAVIS
Filed: 16 Aug 22
Utility
AGONISTS OF ROR GAMMAt
3 Aug 23
Lalgudi S. Harikrishnan, Muthoni G. Kamau, Brian E. Fink
Filed: 7 May 20
Utility
Imidazothiadiazole and Imidazopyrazine Derivatives As Protease Activated Receptor 4 (PAR4) Inhibitors for Treating Platelet Aggregation
3 Aug 23
Jacques Banville, Roger Rémillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dubé, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
Filed: 2 Sep 22
Utility
Crystalline Form of 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE
3 Aug 23
Disclosed is crystalline Form B of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl) amino)-N-(methyl-d3)pyridazine-3-carboxamide.
Daniel Richard Roberts
Filed: 29 Jan 23
Utility
Phosphorous (V)-based Reagents, Processes for the Preparation Thereof, and Their Use In Making Stereo-defined Organophoshorous (V) Compounds
3 Aug 23
The present invention relates to novel phosphorous (V) (P(V)) reagents, methods for preparing thereof, and methods for preparing organophosphorous (V) compounds by using the novel reagents.
Michael Anthony SCHMIDT, Bin ZHENG, Kyle KNOUSE, Justine deGRUYTER, Martin D. EASTGATE, Phil BARAN, William R. EWING, Richard E. OLSON, Ivar M. MCDONALD
Filed: 10 Feb 23
Utility
Immunomodulators
3 Aug 23
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PDL 1 and PD-L 1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Tao WANG, Paul Michael SCOLA, Zhongxing ZHANG
Filed: 7 May 21
Utility
Methods of Diagnosing and Treating Lupus
27 Jul 23
In certain embodiments, the present invention provides a method of treating or preventing lupus (e.g., SLE) in a subject, comprising: (a) identifying the subject as having at least one differentially regulated biomarker selected from CD40, CD40L, CD86, CD80, and PD1; and (b) administering an agent that inhibits the CD40 or CD28 signaling pathway, thereby treating or preventing lupus in the subject.
Laurence Celine Menard, Steven G. Nadler
Filed: 9 Jan 23
Utility
Anti-CSF1R Antibody and Anti-PD-1 Antibody Combination Therapy for Cancer
6 Jul 23
Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
Filed: 21 Dec 22
Utility
Transforming Growth Factor-beta Ligand Traps for the Treatment of Disease
6 Jul 23
The present application relates to methods using Transforming Growth Factor-β (TGF-β) ligand traps.
Raymond Perez, Bruce S. Fischer, Lora Hamuro
Filed: 23 Jun 22
Utility
Small Molecule Inhibitors of GALECTIN-3
6 Jul 23
Prasada Rao Jalagam, Susheel Jethanand Nara, Manoranjan Panda, Murugesan Natesan, Pratik Devasthale
Filed: 10 May 21
Utility
Reagents and Their Use for Modular Enantiodivergent Synthesis of C-P Bonds
6 Jul 23
The disclosure describes chiral P(V)-based reagents and their uses for the modular, scalable, and stereospecific synthesis of chiral phosphines, phosphine oxides and particular oligonucleotides.
Dongmin XU, Nazaret RIVAS-BASCÓN, Kyle W. KNOUSE, Natalia PADIAL, Bin ZHENG, Julien VANTOUROUT, Michael SCHMIDT, Martin D. EASTGATE, Phi BARAN
Filed: 14 Jan 21
Utility
Macrocyclic PAD4 Inhibitors Useful As Immunosuppressant
29 Jun 23
Khehyong Ngu, Christopher Annunziato, John V. Duncia, Daniel Gardner
Filed: 5 Feb 21
Utility
Antibody Variants with Improved Pharmacokinetic Properties
29 Jun 23
The disclosure provides variants of an antibody wherein the variant antibodies have modified net charge properties relative to the corresponding unmodified antibody.
Aaron Yamniuk, Mary Struthers
Filed: 17 May 21
Utility
Substituted Aminopurine Compounds, Compositions Thereof, and Methods of Treatment Therewith
25 May 23
Matthew Alexander, Sogole Bahmanyar, John Frederick Boylan, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, Jingjing Zhao
Filed: 11 Jan 23
Utility
Meayamycin and Its Analogues, Methods for Their Preparation, and Methods of Use
25 May 23
Compounds according to formula (I), where R is as defined herein, have anti-cancer properties.
Dale L. BOGER, Naidu S. CHOWDARI, Sanjeev GANGWAR
Filed: 8 Apr 21
Utility
Crystalline Forms of (9R, 135S)-13- {4-[5-CHLORO-2-(4-CHLORO-1H,2,3- Triazol- 1 -Yl)phenyl] -6-OXO- 1,6-DIHYDROPYRIMIDIN- 1-YL}-3-(DIFLUOROMETHYL)-9-METHYL-3,4,7,15- Tetraazatricyclo [ 12.3.1.0 2·6] Octadeca- 1(18), 2(6), 4, 14, 16-PENTAEN-8-ONE
18 May 23
Disclosed are crystalline forms of Compound (I).
Andrew K. Dilger, Michael A. Galella, Daniel Smith, Theresa M. Ziemba, David Lüdeker, Christos XIOURAS, Dipali AHUJA, Dirk Angelina J. CLEEREN
Filed: 9 Apr 21
Utility
Amide-disubstituted Pyridine or Pyridazine Compounds
18 May 23
Trevor C. Sherwood, Michael G. Yang, John L. Gilmore, Yanlei Zhang, Zili Xiao, Qingjie Liu
Filed: 28 Jan 20
Utility
Sphingosine 1 Phosphate Receptor Modulators
18 May 23
Roger BAKALE, Jeff SCHKERYANTZ, Maurice MARSINI
Filed: 25 Mar 21
Utility
Substituted Pyridopyrimidinonyl Compounds Useful As T Cell Activators
18 May 23
Upender Velaparthi, Richard E. Olson, Chetan Padmakar Darne, Bireshwar Dasgupta, Jayakumar Sankara Warrier, Hasibur Rahaman, Prasada Rao Jalagam, Saumya Roy, Denise Christine Grunenfelder
Filed: 8 Nov 22